ABSTRACT The UL13 protein of the duck enteritis virus (DEV), predicted to encode a Ser/Thr protein kinase, belongs to the family of conserved herpesvirus protein kinases (CHPK), which plays an important role in herpesvirus proliferation. In this study, truncated UL13 was expressed as a fusion protein of approximately 44 kDa using a prokaryotic expression system, and this protein was used to generate a specific anti-UL13 antibody. This antibody detected UL13 starting at 4 h post infection in duck embryonic fibroblast cells and identified UL13 to be present in both the cytoplasm and the nucleus. UL13 RNA was found to be transcribed starting at 2 h post infection, and the synthesis of the UL13 mRNA was found to be sensitive to the protein synthesis inhibitor cycloheximide (CHX) and tolerant of the DNA polymerase inhibitor ganciclovir (GCV). Its nuclear location and status as an early gene suggested that DEV UL13 might play important roles in DEV replication, which was confirmed by comparing the proliferation of a UL13-knockout mutant virus, a revertant virus, and the parent virus in cell culture. The specific mechanisms of UL13 in viral replication need to be further studied.
INTRODUCTION
Duck enteritis virus (DEV), a member of the Alphaherpesvirinae subfamily, induces an acute contagious viral disease resulting in significant economic losses in the waterfowl industry (King et al., 2012) . The DEV CHv strain, which was identified by our group, contains 78 open reading frames, and the UL13 gene of DEV encodes a protein kinase that was predicted to be a member of the conserved herpesvirus protein kinase (CHPK) family (Wu et al., 2012a; Wu et al., 2012b) .
The CHPK family is conserved over the entirety of the Herpesvirinae members (Chee et al., 1989; Gershburg and Pagano, 2008; Jacob et al., 2011) . Functions of CHPK,, including phosphorylation of cellular elongation factor 1 delta (EF-1δ) (Kawaguchi et al., 1998; Kawaguchi et al., 1999; Kato et al., 2001) , modulation of viral replication efficiency (Manfred et al., 2003; Pei-Wen et al., 2008) , involvement in nuclear egress of progeny capsids (Prichard et al., 2005; Yamamoto 2006) , and evasion of the interferon (IFN) response (Hwang et al., 2009; Jiin-Tarng et al., 2009) , have been reported. Additionally, the family's capacity to phosphorylate nucleoside analogues, such as acyclovir (ACV) and ganciclovir (GCV), makes CHPK an attractive potential antiviral target (Michel et al., 1996; Ansari and Emery, 1999; Qiao et al., 2010) . Amino acid sequence analysis showed that the UL13 protein kinase shows more than 35% similarity with reported CHPK, and the exploration of DEV UL13 will not only offer data about the molecular biological characteristics of DEV but also supplement our knowledge of the characteristics and functions of the CHPK family.
In this study, we explored the kinetic class of DEV UL13 using cycloheximide (CHX) and GCV treatments and analyzed the transcription, translation, and intracellular location characteristics of DEV UL13. Then, we analyzed the influence of the UL13 gene on the growth of DEV in cell culture by generating recombinant DEV lacking the UL13 gene. Our results will provide guidance for further exploration of DEV UL13.
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MATERIALS AND METHODS
Plasmids, Viruses, and Cells
pET-32c(+), pKD46, pKD4, pCP20, and DEV CHv-BAC-G were kept in our lab (Wu et al., 2012a; Ying 2015) . DEV CHv-BAC-ΔUL13 and DEV CHv-BAC-ΔUL13 R were generated in this report. Duck embryo fibroblasts (DEF) were propagated in minimal essential medium (MEM; 11095-072, Gibco-BRL, Carlsbad California), supplemented with 10% (v/v) fetal bovine serum (FBS; 10099141, Gibco-BRL, Carlsbad California) at 37
• C with 5% CO 2 . For viral infection, MEM supplemented with 2% FBS was used.
Prokaryotic Expression and Protein Purification
A truncated UL13 gene was PCR-amplified using the T-UL13F/R primers (Table 1) and then cloned into the pET-32c(+) plasmid; then, the recombinant plasmid pET32-UL13T was introduced into CaCl 2 -competent E. coli BL21 (DE3) cells for subsequent protein expression, which was induced by isopropyl-β-Dthiogalactopyranoside (IPTG; 367-93-1, Chemsynlab, Beijing, China). After optimizing the conditions for the highest level of UL13 protein expression, proteins were purified using Ni-NTA-agarose beads (R90101, Invitrogen, Carlsbad California) according to the manufacturer's instructions.
Preparation of Anti-UL13 Polyclonal Antibody
To prepare the polyclonal antibody, 0.5 mg of purified truncated UL13 protein emulsified in complete Freund's adjuvant (F009-1, Sigma, San Francisco, CA) was inoculated into 2 4-month-old rabbits through intradermal injections. A total of one mL of an emulsion containing 0.5 mg purified UL13 protein and 500 μL of incomplete Freund's adjuvant (F5506, Sigma, San Francisco, CA) were inoculated twice (at one-week intervals) into rabbits 2 wk after the first inoculation using subcutaneous injections. Approximately 0.75 mg of the UL13 protein was injected per rabbit. Blood samples were collected one wk after the last inoculation via jugular vein bleeding. The antiserum was harvested, and a preliminary purification was conducted using saturated ammonium sulfate.
Immunoblotting
Truncated UL13 protein expression in E. coli BL21 (DE3) and UL13 protein expression in virus-infected DEF cells at different times (4, 8, 12, 24, 36, 48, 72 and 96 h post infection) were detected using immunoblotting with rabbit anti-DEV and anti-DEV UL13 protein antibodies, respectively, as the primary antibodies (Bei et al., 2010) . A standard protocol was then performed: The proteins were separated via electrophoresis on 12% SDS-PAGE gels and transferred to polyvinylidene fluoride (PVDF; 1620177, Bio-Rad, Hercules California) membranes using a semidry transfer cell apparatus. The membrane was incubated in blocking buffer (PBS containing 1% BSA) for one h and then washed. The membrane was then incubated with the primary antibody, diluted to 1:500 in blocking buffer containing 0.05% Tween-20 (ST825, Beyotime, Shanghai, China) for one h and then washed. Horseradish Peroxidase (HRP) -conjugated goat anti-rabbit IgG (ZB-2301, ZSGB-BIO, Beijing, China), diluted 1:3000 in blocking buffer containing 0.05% Tween-20, was incubated with the membrane for 30 min, followed by washing. The membrane was developed using the electrochemiluminescence (ECL) immunoblotting detection reagents (170-5060, Bio-Rad, California) according to the manufacturer's instructions.
Real Time PCR (RT-PCR)
Total RNA was isolated from virus-infected cells at different times (1, 2, 4, 8, 12, 24, 36, 48, 60, 72, 84 and 96 h post infection) using the NRAiso Plus kit (9108, TaKaRa, Dalian, China) and was subsequently reverse transcribed into cDNA using the PrimeScript R RT reagent Kit with gDNA Eraser (RR047A, TaKaRa, Dalian, China) (Huang et al., 2013) . The PCR was performed in a 20-μL-reaction volume containing 10 μL of SYBR Fast qPCR Mix (RR430A, TaKaRa, Dalian, China), one μL of each primer (RT-UL13 F/R or β-actin F/R; Table 1), one μL of cDNA, and 7 μL of ultrapure water. The thermal cycling procedure included initial denaturation for one min at 95
• C, followed by 45 cycles of denaturation at 95
• C for 5 s, annealing at 59
• C for 20 s, and extension at 72 • C for 25 seconds. Triplicate experiments were performed to analyze the gene expression of UL13 and β-actin, and the relative transcription levels of the DEV UL13 gene were calculated using the 2 −ΔCt method (Liu et al., 2015) . To evaluate the efficiency of each assay, standard curves were constructed, amplifying 10-fold serial dilutions of pET32-UL13T and pGM-T/β-actin (Lin et al., 2013) .
Pharmaceutical Inhibition Test
Pharmaceutical inhibition was performed to evaluate the DEV UL13 gene expression patterns. DEF cells were infected with the DEV CHv strain at 100 TCID 50 per each well and incubated for one hour. DEF were treated with ganciclovir (GCV; MB1693, Meilunbio, Dalian, China) at 300 μg/mL immediately after DEV infection or cycloheximide (CHX; MB2208, Meilunbio, Dalian, China) at 100 μg/mL for one h prior to DEV infection. Then, total RNA was isolated from these 
a Sequences of restriction endonuclease sites are underlined.
treated DEF cells and subsequently reverse transcribed into cDNA. The cDNA was used for subsequent PCR analysis (Primers UL13 F/R and Primers β-actin F/R, Table 1 ), and the product was identified using a 1% agarose gel.
Immunofluorescence Assay
Slide-cultured DEF cells were infected with DEV; after 48 h post infection, the slides were fixed with 4% paraformaldehyde (AR-0211, http://dgcs.biomart.cn), permeabilized with 0.1% Triton X-100 (T8200, Solarbio, Beijing, China) and blocked with BSA for one hour. The cells were then incubated with the rabbit anti-UL13 antiserum (at a 1:200 dilution) for one h at 37
• C and then with a 1:200 dilution of goat anti-rabbit antibody conjugated to fluorescein isothiocyanate (FITC) (ZF-0311, ZSGB-BIO, Beijing, China) for 30 minutes. The nuclei were stained with 4', 6-diamidino-2-phenylindole (DAPI; C0065, Solarbio, Beijing, China). The cells were observed using a Nikon ECLIPSE 80i microscope (Nikon, Tokyo, Japan).
Construction of Recombinant Viruses
To create the DEV CHv-BAC-ΔUL13 virus, a recombinant mutant with the UL13 gene deleted, the target segment (UL13 left arm-FRT-Kan-FRT-UL13 right arm) was PCR-amplified using the ΔUL13 F/R primers (Table 1) . Then, the infectious clone DEV CHv-BAC-ΔUL13-G was generated by employing a recombinating system based on the genetic manipulation of the DEV CHv-BAC-G infectious clone (Sopher and Spada, 2006; Bowles and Blaho, 2011; Poteete, 2013; Ying, 2015) . Briefly, the pKD46 plasmid, which encodes the recombination genes exo, beta, and gam under the tight control of a ParaB promoter, was first introduced into E. coli DH10B containing the DEV CHv-BAC-G plasmid by electrophoretic transfer. In this system, the UL13 coding sequence was replaced by the target segments amplified from the pKD4 plasmid. Next, the pCP20 plasmid was transferred into the above cells, which contain DEV CHv-BAC-ΔUL13-G and kanamycin-resistant gene cassette. Removal of the kanamycin-resistant cassette was accomplished by incubation at 30
• C for 8 h then at 42
• C overnight. Then, the infectious clone DEV CHv-BAC-ΔUL13-G was identified by sequencing and RFLP analysis. The infectious clones of the revertant, DEV CHv-BAC-ΔUL13R-G, were generated based on the same method used above but with a different target segment (UL13 gene-FRT-Kan-FRT-UL13 right arm), which was fusion PCR-amplified using the UL13 F/R and FRT-Kan F/ΔUL13 R primers (Table 1) . Finally, the DEV CHv-BAC-ΔUL13 and DEV CHv-BAC-ΔUL13R recombinant viruses were rescued; freshly prepared DEV CHv-BAC-ΔUL13-G and DEV CHv-BAC-ΔUL13R-G plasmids were transfected into DEFs for one to 10 d, and the cells were examined by fluorescence microscopy until green fluorescence protein seemed sufficiently expressed, at which point, they were harvested after freeze-thawing 3 times. After amplifying the DEV CHv-BAC-ΔUL13 and DEV CHv-BAC-ΔUL13R viruses, viral PCR identification of the target region was performed using forward/reverse primers (Table 1) .
Plaque Assay
DEFs were incubated with DEV CHv-BAC, DEV CHv-BAC-ΔUL13, or DEV CHv-BAC-ΔUL13R at 37
• C for 2 hours. The plates were then overlaid with an equal-parts mixture of 2 × MEM and 0.5% methylcellulose (9004-67-5, J & K SCIENTIFIC LTD., Beijing, China) after discarding unabsorbed particles. After incubation at 37
• C for 6 d, the cells were fixed with 4% paraformaldehyde and stained with 0.05% crystal violet (C3886, Haoran Bio, Beijing, China) (Park et al., 2014) . Plaque areas were then measured with ImagePro Plus software, with 50 plaques chosen at random for each virus. 8, 12, 24, 36, 48, 72 and 96 h, and immunoblotting was used to analyze UL13 protein expression. Rabbit anti-UL13 and anti-β-actin antiserum were used as the primary antibodies, and HRP-conjugated goat anti-rabbit IgG was used as the secondary antibody. The membrane was developed using ECL immunoblotting detection reagents. M, pre-stained protein molecular weight marker (Bio-Rad Code: 161-0373).
Growth Curve Assay
Duck embryo fibroblasts cells were infected with DEV CHv-BAC, DEV CHv-BAC-ΔUL13, or DEV CHv-BAC-ΔUL13R at 200 TCID 50 . The cells were maintained in MEM supplemented with 2% FBS, and samples of the cells and supernatants were separately harvested at 6, 12, 24, 48, 72, and 96 h for the growth curve assay after being freeze-thawed 3 times (Li et al., 2011) . The growth curve was recorded via measuring the TCID 50 , which was calculated with the ReedMuench method, of the samples at different time points and triplicate experiments were performed.
Ethics Statement
Animals were handled in strict accordance with good animal practices as defined by the local animal welfare The average values of DEV UL13 and β-actin transcripts were calculated at the corresponding post-infection time points using Excel, then the relative content of DEV UL13 transcripts was calculated using the 2 −ΔCt method and the graph was made using GraphPad Prism 6.0 software. Each time point was measured in triplicate and is presented as the mean and standard error. (C) The pharmacological inhibition tests using conventional PCR as a read-out. "+", cDNA of DEV-infected DEF without inhibitor added; "GCV", cDNA of DEV-infected DEF with the addition of GCV; "CHX", cDNA of DEV-infected DEF with CHX added; "-", cDNA of DEF without DEV-infected. The β-actin and UL13 on both sides represented primers used in the conventional PCR reaction. M, DNA marker (DL2000).
bodies. Animal work was performed at Sichuan Agriculture University and was reviewed and approved by the Sichuan Agriculture University Ethics Committee in January 2014.
RESULTS
Expression of DEV UL13 Protein
To identify the temporal expression of DEV UL13 in DEV-infection DEF, we first prepared an anti-UL13 antibody. We expressed a truncated UL13 protein (amino acids 162 to 389) in E. coli BL21 (DE3) cells, confirmed the optimum expression conditions to be 30
• C with 0.2 mM IPTG induction for 5 h, and then purified the truncated UL13 protein as described in the materials and methods section ( Figure 1A ). This purified, truncated UL13 protein can be recognized by the anti-DEV polyclonal antibody ( Figure 1B) . We obtained the anti-UL13 polyclonal antibody by inoculating rabbits with the purified 44 kDa protein ( Figure 1C) ; immunoblotting with this antibody was used to observe the dynamic changes in UL13 protein expression in DEV-infected DEF cells. The results revealed that DEV UL13 encoded an approximately 60 kDa protein, which could be detected at 4 h post infection and peaked at 24 h post infection ( Figure 1D ).
Duck Enteritis Virus UL13 is An Early Gene
We investigated the relative expression of the DEV UL13 gene in DEV-infected DEF cells at different time points using quantitative RT-PCR, which is the most sensitive technique currently used to analyze gene expression (Farrell, 2010) . First, standard curves, plotting the plasmid copy number against the Ct values of UL13 (Y = −3.323X + 2.325) and β-actin (Y = −3.307X + 5.567), were established to evaluate the efficiency of the assays. The results were confirmed by the approximately identical amplification efficiencies of the UL13 gene and β-actin (100 and 100.6%, respectively), with a correlation coefficient of 1.000 and 0.996, respectively (Giulietti et al., 2001) . Notably, the specificity of the primer sets was verified by the presence of single-peak melting curves (data not shown).
With the primers validated, RT-PCR was then performed to analyze UL13 transcript levels. The results showed that transcription of UL13 became detectable at 2 h post infection and peaked at 24 h (Figure 2A) , which was consistent with its translation ( Figure 1D ). The relative transcription of UL13 peaked at 48 h then decreased ( Figure 2B ).
Sequential blockade with CHX was used to express immediate-early gene products in hepersvirus-infected cells; metabolic blockade with GCV was used to allow expression of hepersvirus early proteins. The specific inhibitors of viral DNA replication or protein synthesis, GCV and CHX, respectively, were used to explore the synthesis of the UL13 mRNA with respect to the replicative cycle of DEV. We observed that the expression of DEV UL13 was sensitive only to CHX, and no reduced UL13 expression occurred in the presence of GCV ( Figure 2C ). Our results suggest that DEV UL13 is an early gene. The intracellular distribution of DEV UL13 protein in DEV-infected DEF. DEV-and mock-infected DEFs were fixed with 4% paraformaldehyde, and then IFA was performed. The rabbit anti-UL13 antiserum was used as a primary antibody, and goat anti-rabbit antibody conjugated to FITC (green) was used as the secondary antibody. Nuclei were stained with DAPI (blue). Images were recorded in the FITC channel (a2-f2) and the DAPI channel (a1-f1) using a 60× objective and then merged with the SPOT software (a-f).
Distribution of DEV UL13 Protein in DEV-infected DEF
The localization of the DEV UL13 protein had not yet been reported, so we examined its intracellular distribution in DEV-infected DEF via IFA using rabbit anti-UL13 antiserum as the primary antibody. We collected the IFA pictures in different experimental groups and different visual fields at 48 h post infection. As shown in Figure 3 , UL13 protein-specific fluorescence could be detected in both the cytoplasm and nucleus (Figure 3b-f) , and no signal was observable in mockinfected DEF (Figure 3a) .
UL13 is Important for DEV Proliferation in Cell Culture
To examine the effect of UL13 on viral proliferation, we constructed DEV CHv-BAC-ΔUL13, which was a UL13-deletion mutant, and DEV CHv-BAC-ΔUL13R (a revertant) ( Figure 4A ). By RFLP analysis and sequencing, we determined that the DEV CHv-BAC-ΔUL13 and DEV CHv-BAC-ΔUL13R recombinant viruses were mutated only at their appropriate target site ( Figure 4B and C) . A plaque assay indicated that the DEV CHv-BAC-ΔUL13 could grow in DEF but led to a significantly smaller plaque size, whereas the DEV CHv-BAC-ΔUL13R exhibited a normal phenotype similar to DEV CHv-BAC ( Figure 5A ). The growth curve revealed a lower titer for DEV CHv-BAC-ΔUL13 compared to both DEV CHv-BAC and DEV CHv-BAC-ΔUL13R in both the supernatant and cells during the infection period ( Figure 5B ). These data suggest that the reduced plaque size and weaker replication resulted from the deletion of UL13.
DISCUSSION
Herpesvirus proteins are synthesized in an orderly cascade. The viral genes are divided into immediateearly (α), early (β), and late (γ) genes according to their order of gene expression and the mechanisms driving them (Roizman and Campadelli-Fiume, 2007; Smith-Donald and Roizman, 2008) . In this report, we demonstrated that DEV UL13 was an early gene. This is inconsistent with the CHPK members in Alphaherpesvirinae that have been reported, such as PRV UL13 and HSV UL13, which have been proven to be late genes (Daikoku et al., 1997; Tombacz et al., 2009) . According to current reports, the CHPK in Betaherpesvirinae and Gammaherpesvirinae belong to the early-late gene or late gene groups (Michel et al., 1996; Junsoo Park et al., 2000; Gershburg et al., 2004) , except that of HHV U69, which belongs to the early gene group (Yuji et al., 2008) . This may be related to the roles each CHPK plays in viral replication. As we all know, early proteins regulate viral replication and the expression of late genes. It has been reported that HSV UL13 indirectly regulated the expression of a subset of alpha and gamma proteins in infected cells (Purves et al., 1993; Bastian and Rice, 2009) , although it was identified to be a late protein. And, we found that the replication of the DEV mutant with UL13 deleted was significantly weakened in vitro, while it was reported that the titers of UL13-inactivated HSV mutant and wild-type HSV was equal in vitro (Coulter et al., 1993) . It was suggested that DEV UL13 might play an important role in DEV replication. Given the early kinetics of DEV UL13, we wanted to explore the function of this protein, beginning with its dynamic distribution in DEV-infection DEF. We observed that the UL13 protein was located in both the cytoplasm and nucleus. Homologues of DEV UL13 in Betaherpesvirinae and Gammaherpesvirinae, such as human herpesvirus (HHV) U69, Epstein-Barr virus (EBV) BGLF4, and human cytomegalovirus (HCMV) UL97, have all been shown to locate and function primarily in the nucleus (De, et al., 2002; Gershburg et al., 2004; Michel et al., 1998) . Information about the localization of CHPK in Alphaherpesvirinae is limited; it has been reported that HSV-1 and HSV-2 UL13 can be purified from nuclear extracts of HSV-1-and HSV-2-infected cells (Daikoku et al., 1997) , and UL13 proteins have been proven to participate in the phosphorylation of nuclear lamina components to facilitate the nuclear egress of progeny capsids in cells infected with HSV-1 or HSV-2 (Yamamoto et al., 2006; Cano-Monreal et al., 2009 ). In cytoplasm, it has been reported that the CHPK of the three different herpesvirus subfamilies are able to phosphorylate translation elongation factor 1 delta (EF-1δ) to regulate and/or stimulate the translation process in infected cells (Jacob et al., 2011) and that the CHPK also can phosphorylate viral tegument and membrane proteins in the cytoplasm to facilitate viral spread and entry, which is best documented for alphaherpesviruses (Morrison et al., 1998; Ng et al., 1998; Geiss et al., 2001; Kenyon et al., 2001; Kenyon et al., 2002) . The location of DEV UL13 reflects the role it plays in different steps of the viral replication cycle. Combined with its early kinetics and influence on viral proliferation, the functions that DEV UL13 plays in the nucleus will be explored in our next investigation. The digital images were analyzed using Image-Pro Plus software and the statistical analyses were performed using GraphPad Prism 6.0 software. * * : P < 0.01. (B) Growth curve. DEF were infected with DEV CHv-BAC, DEV CHv-BAC-ΔUL13, or DEV CHv-BAC-ΔUL13R at a titer of 200 TCID 50 and harvested at 6, 12, 24, 48, 72, and 96 hours post infection. The curves were generated based on the titers of the different harvests, by testing for the TCID 50 using Excel. And the significant difference analyses between DEV CHv-BAC and DEV CHv-BAC-ΔUL13 were performed using GraphPad Prism 6.0 software. * : P < 0.05, * * : P < 0.01.
